On 2 December 2025 an extraordinary general meeting was held in Enorama Pharma AB (publ), reg. no. 556716-5591 ("Enorama Pharma" or the "Company"). Below is a summary of the adopted resolution.
Resolution to approve related party transaction regarding loan agreement.
The general meeting resolved to approve the loan agreement entered into between Enorama Pharma and the major shareholder DS Global Pte Limited ("DS Global") on 7 November 2025 which was conditioned on the subsequent approval by the general meeting (the "Loan Agreement"). Through the Loan Agreement, DS Global provides a loan facility of USD two million (2,000,000) to Enorama Pharma. Further information regarding the Loan Agreement has been supplied in the notice of the extraordinary general meeting which was published on the 12 November 2025 as well as in the board of directors report which was published on the same day.
It was noted that shares and votes held directly or indirectly by DS Global, or other companies under the same control, was not taken into account in the resolution.
Contact:
Enorama Pharma AB (publ)
Bengt Jönsson, deputy CEO
Strandvägen 7A, 114 51 Stockholm
Enorama Pharma AB (publ) is listed on Nasdaq First North Growth Market.
ABOUT ENORAMA PHARMA
Enorama Pharma's vision is to be a leading global manufacturer and supplier of consumer-friendly, oral nicotine products. The Company intends to expand through product and brand development and by establishing strategically important partnerships. For more information, visit www.enorama.se